Pankaj Vashi, MD
Gastroenterology · Zion, ILNPI 1336136258
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,273 of the $3,023 with a category attached, or 75.2%. 30 manufacturers reported payments, led by US Endoscopy at 24.8% of the total. Reporting peaked in 2024 at $1,558 and has fallen 92.7% since, to $113 in 2025.
Across 79 payments — averaging $38.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Endoscopy$750
- Merck$277
- Steris Corporation$254
- Gilead$246
- AbbVie$189
- Fresenius Kabi USA, LLC$185
- plus $1K from 24 others
What the payments were for
- Consulting fees$75025%
- Food & beverage$2,27375%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Endoscopy | 1 | $750 |
| Merck | 11 | $277 |
| Steris Corporation | 2 | $254 |
| Gilead | 2 | $246 |
| AbbVie | 9 | $189 |
| Fresenius Kabi USA, LLC | 2 | $185 |
| Lilly USA, LLC | 7 | $130 |
| AstraZeneca | 5 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $101 |
| Pfizer | 5 | $86 |
| Novartis | 4 | $83 |
| Boston Scientific | 1 | $82 |
| Daiichi Sankyo Inc. | 2 | $52 |
| Lexicon Pharmaceuticals, Inc. | 2 | $49 |
| Rigel Pharmaceuticals, Inc. | 2 | $47 |
| Acacia Pharma Inc | 4 | $43 |
| Digestive Care, Inc. | 1 | $40 |
| Braintree Laboratories, Inc. | 2 | $35 |
| Springworks Therapeutics, Inc. | 1 | $35 |
| GSK | 1 | $27 |
| Eisai Inc. | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Amgen | 1 | $24 |
| Blueprint Medicines Corporation | 1 | $22 |
| Vivus LLC | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Incyte Corporation | 1 | $19 |
| Shire North American Group Inc | 1 | $16 |
| Exelixis Inc. | 1 | $15 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,023 in reported general payments places this provider in the 65th percentile of 787 gastroenterology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 18 | $379 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Zion
- David RubinChicago$1.5M
- Stephen HanauerChicago$1.4M
- Steven FlammChicago$1.3M
- Amar NaikDes Plaines$1.2M
- Darren BrennerChicago$1.1M
- Jonathan RosenbergGurnee$1M
- Daksesh PatelEvanston$745K
- Russell CohenChicago$690K
- Parambir DulaiChicago$668K
- Christopher ChapmanChicago$645K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.